Background Introduction of human papillomavirus (HPV) vaccination in settings with the highest burden of HPV is not universal, partly because of the absence of quantitative estimates of country-specifi c eff ects on health and economic costs. We aimed to develop and validate a simple generic model of such eff ects that could be used and understood in a range of settings with little external support.
Introduction
Estimates of the possible health and economic eff ects of human papillomavirus (HPV) vaccination provide vital evidence to support the introduction of the vaccine into national programmes. WHO recommends that costeff ectiveness is considered before introduction of the vaccine, 1 and many high-income countries started such assessments before introduction. 2 In low-income and middle-income countries (LMICs), such assessments are less common, but are equally, if not more, important because of insuffi cient funding for public health interventions and the need to establish the fi nancial case for vaccination to ministries of fi nance. 3 For example, the cost of the entire Expanded Programme on Immunization vaccine schedule (Bacillus Calmette-Guérin, diphtheria-tetanus-pertussis, oral polio, and measles) was estimated to be about US$17 per fully vaccinated child. 4 Conversely, the price for three doses of HPV vaccine was estimated to be about $13·50 through GAVI Alliance procurement, $39 at the lowest non-GAVI public sector indicative price, and more than $300 in high-income countries. 5 Some reports have suggested that overinvestment in vaccines for lowburden diseases in LMICs has prevented vaccines against diseases of greater public health concern from being introduced. 6 To avoid misplaced priorities, many international funders such as the GAVI Alliance are guided by forecasts of the eff ect of disease and costeff ectiveness to decide which vaccination programmes to fund. 7 However, assessments of cost-eff ectiveness of HPV vaccination often use complex models with data and expertise requirements that are prohibitive in many settings. Application of such models to resource-poor settings might require dependence on external consultants, which can sometimes restrict the involvement of local analysts and policy makers and, consequently, the eff ect that these results have on local decisions. 3 Furthermore, existing analyses have been done with various model types, ranging from simple static models that only consider direct eff ects, to complex individual-based transmission dynamic models. This variation in model types restricts the comparability of their results, 8-10 because diff erent model types rely on diff erent simplifying assumptions.
To address this knowledge gap and support evidencebased vaccine introduction in countries without reliable economic assessments of HPV vaccination, we aimed to develop a generic model of the health and economic eff ects of female HPV vaccination that uses straightforward calculations and data requirements and transparent assumptions so that it can be used and understood in a range of settings with little external support.
We also aimed to validate the model against other published HPV models, assess the cost-eff ectiveness of HPV vaccination in 179 countries with a particular focus on LMICs, and forecast reduction in the global cervical cancer burden and health disparities after HPV vaccination, with diff erent vaccine uptake scenarios including GAVI Alliance strategic demand forecasts.
Methods

Model overview
We developed the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) as a Microsoft Excelbased model that estimates the health and economic eff ect of vaccination of girls against HPV before sexual debut. We modelled the eff ect of the vaccine in terms of reduction in age-dependent incidence of cervical cancer and mortality in direct proportion to vaccine effi cacy against HPV 16/18, vaccine coverage, and HPV type distribution (appendix p 1). We assumed that no changes to methods of cervical cancer screening or uptake occur during the time horizon of the model-ie, the period during which model results are followed (in most cases, the lifetime of the vaccinated cohort). We further assumed that vaccines provide lifelong protection, as suggested by the absence of vaccine failures in longterm follow-up of vaccinated cohorts, and statistical extrapolation of immunogenicity data. 11 We did not consider indirect eff ects (herd protection), thus the model provides a conservative lower bound on vaccine eff ect.
Validation
To assess validity of our model, we used PRIME to replicate results of all relevant published cost-eff ectiveness analyses of HPV vaccination in LMICs, as identifi ed in a recent systematic review. 8 We extracted key parameters (vaccination coverage, vaccine effi cacy, vaccination age, cost per vaccinated girl, cost of cervical cancer treatment, discount rate, age-dependent mortality, age-dependent cervical cancer mortality, cervical cancer incidence, and HPV 16/18-dependent fraction of cervical cancers) from every study and used these as input parameters for PRIME. We used Cohen's kappa to test agreement between PRIME and published models about whether vaccination was very cost eff ective in the countries examined. To further assess validity, we made a separate comparison with results of a cost-eff ectiveness analysis of HPV vaccination in the GAVI-72 countries (countries that are eligible for GAVI Alliance support in phase 2 of their strategic plan ). 12 Appendix pp 2-10 gives further details about study selection and data extraction.
Projections for 179 countries
We parameterised PRIME with data from 179 countries for which UN population estimates are available. 13 Data for size of vaccination cohort, likely vaccine procurement and administration costs, incidence of cervical cancer, treatment costs, all-cause and cervical cancer-specifi c mortality, gross domestic product (GDP) per head, and proportion of cancers due to HPV16 and HPV18 were obtained from global datasets produced by WHO, the World Bank, the International Agency for Research on Cancer, and other sources (appendix pp 2-10). [13] [14] [15] [16] [17] [18] [19] [20] We estimated the eff ect of vaccination of the entire cohort (58 million 12-year-old girls) in terms of the number of cases of cervical cancer, deaths, and disabilityadjusted life-years (DALYs) averted during their lifetimes. We assumed full vaccination coverage of the relevant cohort for illustrative purposes. We measured costeff ectiveness by comparing the cost per DALY averted (in 2011 US$) with thresholds of GDP per head, which is often used as an indication that an intervention is very cost eff ective, and three times GDP per head, used to indicate that an intervention is cost eff ective. 21 We did sensitivity analyses by varying key parameters (vaccine costs, cancer costs, cancer incidence, and cancer mortality) by plus or minus 25%, with cancer incidence and mortality from 2008 estimates (rather than 2012), and setting discount rates to 0% or 6%. We also explored the eff ect of adjustment of regional cancer costs by country-level variation in GDP per head (in 2011 US$; appendix p 6).
To explore between-country equity of present use of HPV vaccines, we estimated the potential eff ect of HPV vaccination on reduction of the burden of cervical cancer for countries that had introduced country-wide vaccination by Jan 1, 2012, and by Oct 1, 2013, and countries that are yet to introduce vaccination nationwide. National vaccines introduced by 2012 were determined See Online for appendix from data by Markowitz and colleagues, 22 whereas introductions by October, 2013, were obtained from WHO (Wang S A, WHO, personal communication). We did a similar analysis to explore associations between eff ect of vaccine and presence of an existing cost-eff ectiveness evaluation of HPV vaccination, as reported in the four most recent systematic reviews of HPV vaccination. 8, [23] [24] [25] We included studies focusing only on one country or a small number of countries (fewer than ten in the same publication).
To assess the quality of model parameters, we rated data for cancer incidence, cancer mortality, distribution of HPV type in cancer, and distribution of cancer stage at detection for every country as either "satisfactory" or "unsatisfactory". Ratings were based on whether representative, good quality within-country data were available (appendix pp 6, 7, [25] [26] [27] [28] [29] [30] .
Projections for GAVI countries
The GAVI Alliance produced HPV vaccination coverage estimates for 2009-12 and strategic demand forecasts to 2032 for 73 countries (the GAVI-72 countries and South Sudan; Johnson H, GAVI Alliance, personal communication). We extrapolated fi gures (obtained with permission from the GAVI Alliance) for 71 countries (all except South Sudan and Kiribati, for which population projections were not available) by assuming that the proportion of 12-year-old girls who received HPV vaccination remained at the fi gures for 2032, even though the absolute number of doses would change because of fl uctuations in the size of the 12-year-old female population. We then used these forecasts as inputs to PRIME (together with existing inputs for disease burden) to project the eff ect of vaccine on cervical cancer cases and deaths. We did sensitivity analyses by varying cancer incidence and mortality by plus or minus 25%. We modelled 61 vaccinated cohorts in these 71 GAVI-72 countries (one for every year from 2009-70), and aggregated the projected future eff ect of vaccination of every cohort to produce results by calendar year. In addition to this base case scenario, we also considered the eff ect of other scenarios: fi rst, no further vaccine introductions or increases in coverage beyond 2014 (worst case); second, vaccine introductions and increases in coverage in 2012-32 based on GAVI Alliance strategic demand forecasts (middle variant); and third, the entire cohort of 12-year-old girls in every GAVI-72 country is vaccinated every year from 2014 (best case).
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The views expressed are those of the authors and do not necessarily represent the views of WHO. RH is a staff member of WHO. The corresponding author had full access to all data in the study and fi nal responsibility for the decision to submit for publication.
Results
In our validation assessment, PRIME generally provided incremental cost-eff ectiveness ratios that were very close to those of the original country-based study when the original study parameters were used (fi gure 1). With a threshold of GDP per head as very cost eff ective, PRIME reproduced the qualitative conclusions (in terms of vaccination being very cost eff ective or not) for 24 of 26 countries (k=0·85) in 17 published studies. For the GAVI-72 analysis, both PRIME and Goldie and colleagues 12 produced much the same conclusion for all 72 (k=1) countries: female HPV vaccination would be very cost eff ective in all countries except Afghanistan and the Democratic Republic of Congo.
Appendix pp 17-24 shows the full results.
Vaccination of a cohort of 58 million girls before sexual debut, which represents full coverage in 179 countries of Figure 2 shows the number of prevented cervical cancers per 100 000 girls vaccinated for countries with and without national HPV vaccination programmes. Of 33 countries where HPV vaccines are likely to have the greatest eff ect (>2500 cancers prevented per 100 000 girls vaccinated), only four had introduced national vaccination by Jan 1, 2012 (Fiji, Peru, Romania, and Rwanda), and an additional three had between Jan 1, 2012, and Oct 1, 2013 (fi gure 2). Conversely, of 55 countries where HPV vaccines are likely to have the least eff ect in comparison (<1000 cancers prevented per 100 000 girls vaccinated; mostly in western Europe and North America), 24 have introduced vaccination.
The number of cancers that could be prevented per 100 000 girls vaccinated was signifi cantly lower (2-sided t test p=0·011) in the 46 countries that have introduced national vaccination (2013: median 980, IQR 700-1700) than in the 133 countries that have not (1600, 1000-2300; fi gure 3). The disparity is seen in every WHO region except the African Region (fi gure 3). However, worldwide, the disparity narrowed between 2012 and 2013, when the number of cancers that could be prevented per 100 000 girls vaccinated in the 34 countries with national vaccination was lower (median 930, IQR 690-1200) than in 2013. The improvement has mainly been because of new vaccine introductions in the African and Americas regions since 2012. When parameterised with global data, HPV vaccination of young girls is cost-eff ective (less than three times GDP per head) in all but six countries (mostly in the Eastern Mediterranean region) with low reported incidence of cervical cancer compared with other countries with similar income, and very cost-eff ective (below GDP per head) in 156 (87%) of 179 countries (appendix pp 15-24).
Projections of the quality of data that informs most high-income countries and some middle-income countries (including China, Brazil, Argentina, and South Africa) was judged satisfactory in all categories assessed. However, data quality for most countries in African and Eastern Mediterranean regions and Central Asia was judged unsatisfactory in almost all categories assessed (appendix pp [25] [26] [27] [28] [29] [30] .
In the sensitivity analyses, our overall results were robust to adjustments to any of the key parameters apart from discount rates (table 2) ; across all scenarios HPV vaccination was cost-eff ective in all but three to eight countries. However, discount rates have a large eff ect; setting discount rates to 0% makes vaccination cost eff ective in all countries (and very cost eff ective in all but three countries), whereas setting it to 6% makes vaccination not cost eff ective in 26 countries (table 2) .
In terms of association between vaccine introduction and previous cost-eff ectiveness assessment, presence of a published economic evaluation of HPV vaccination was strongly associated with having introduced a universal vaccination programme. Only 28 (18%) of 153 countries without published economic evaluations had universal vaccination programmes. These countries mainly had upper-middle incomes or were high income with small populations (such as Greece, New Zealand, Romania, Sweden, and the United Arab Emirates). Only four countries with low and lower-middle income fell into this category (Bhutan, Fiji, the Federated States of Micronesia,
Figure 3: Eff ect of vaccine (potential number of cervical cancers prevented per 100 000 girls vaccinated) in countries that have and have not introduced national vaccination (for which there are at least two countries in the relevant category)
Data show year of vaccine introduction, median cancers avoided per 100 000 vaccinated (IQR), and number of countries. The horizontal axis shows all countries in the relevant category arranged in increasing order of vaccine eff ect, so a high line shows a high burden of preventable disease. Figure 4 shows the projected eff ect of HPV vaccination in the GAVI-72 countries, assuming that they adopt vaccination on the schedule suggested by GAVI Alliance strategic demand forecasts. According to these forecasts, vaccine demand in GAVI-72 countries is likely to increase sharply in 2015-20; this increase is likely to produce large reductions in incidence and mortality of cervical cancer after 2050 (fi gure 4). By 2070, vaccination could prevent almost 200 000 cases of cervical cancer and more than 100 000 deaths every year. Equivalent fi gures for 2030 are 9000 cancers and 3000 deaths prevented, and for 2050 are 40 000 cancers and 20 000 deaths prevented. These projections assume that no related interventions (such as cervical screening or increased access to cancer treatment) are introduced where they did not previously exist. If all GAVI-72 countries are able to adopt HPV vaccination in 2014 with complete coverage, then the maximum eff ect of global vaccine would be 400 000 fewer cases of cervical cancer and 200 000 fewer deaths every year by 2070. The largest country contributing to the diff erence is India, which at present is not forecast to introduce HPV vaccination. If no new vaccines are introduced after 2013, then only around 2000 cervical cancer cases and 1000 cancer deaths will be prevented every year after 2070 in GAVI-72 countries.
Discussion
To our knowledge, this study is the fi rst assessment of the likely health and economic eff ect of female HPV vaccination in 179 countries. By use of a straightforward model, which was validated against existing costeff ectiveness studies in LMICs, we report that HPV vaccination is likely to be very cost eff ective in most countries and cost-eff ective in almost every country in the world (panel). Furthermore, cost eff ectiveness of HPV vaccination could be better than presented, once further benefi ts not included in our analysis are incorporated such as herd protection, protection against non-cervical cancers and genital warts (in both females and males), and cost savings as a result of reduced need for cervical screening and treatment. Moreover, in high-income countries, which publicly procure HPV vaccines through competitive tenders, vaccine purchase prices could be substantially lower than the US retail price assumed. Hence a country's failure to show cost-eff ectiveness in this analysis is an indication that cost-eff ectiveness of HPV vaccination needs to be investigated more closely in that country before introduction of a vaccination programme, rather than as a reason to rule out vaccination.
Only three economic evaluations of HPV vaccination on a multiregional scale have been published. 12,16,26 Two reviews 12,16 were done before GAVI Alliance support for HPV vaccine introduction was announced. Ginsberg and colleagues 16 assessed the cost-eff ectiveness of female HPV vaccination by WHO subregion using a state transition model, but did not provide assessments of eff ect or cost-eff ectiveness at country (rather than regional) level. Goldie and colleagues 12 assessed the costeff ectiveness of HPV vaccination in 72 low-income countries. Both these assessments used more complex models than did ours; however, their results agree with our overall conclusions that HPV vaccination is likely to be very cost eff ective in most parts of the world. A third global analysis was published more recently, 26 but again this study did not provide country-level assessments. Furthermore, this analysis 26 mainly extrapolated data from high-income and middle-income countries, so its validity in low-income countries where most cervical cancer burden lies is uncertain. In addition to these multiregional models, a series of regional costeff ectiveness analyses of HPV vaccination have been published for sub-Saharan Africa, 27 the Middle East, 28 North Africa, 28 Central Europe, 29 Eastern Europe, 29 and Central Asia. 29 Our study is unique in its assessment of the eff ect and cost-eff ectiveness of HPV vaccination at country level in almost every country worldwide, with a particular focus on low-income countries and intercountry disparities. One limitation is that we have, out of necessity, relied on global datasets instead of data collected within every country. We note that for many countries (especially in African and Eastern Mediterranean regions) data quality are poor and often extrapolated from other countries in the region. Hence, we might not have comprehensively addressed between-country variations within the same region and income. Consequently, our results should be used mainly to understand between-region variations and not to inform decisions on a national level. For national decisions, PRIME can be used as a technique to guide country-led data collection to inform more contextualised results.
Our validation exercise shows that PRIME provides similar results to those obtained by more complex costeff ectiveness models for evaluation of HPV vaccination of girls before sexual debut. To our knowledge, our model is the fi rst to be validated by quantitative comparison of results with such a broad range of published models. Admittedly, many of the modelling studies in the published work have used the same model or are adaptations of previous models. 8 However, the consistency of our results with almost all literature suggests that the eff ect and cost-eff ectiveness of vaccinating girls before sexual debut at high coverage can be reasonably predicted from data for cancer incidence, distribution of HPV type in cancer, and vaccination costs alone.
Our analysis has limitations. PRIME does not model transmission of HPV infection or the natural history of precancerous cervical disease, and many of the parameters we use in this analysis are based on global datasets that extrapolate data from a small number of countries. PRIME also does not model introduction of non-vaccine interventions to reduce cervical cancer burden such as screening. Such interventions are important to consider alongside vaccination as part of a comprehensive strategy to control cervical cancer. 30 Hence, PRIME complements models that have additional features to accurately capture events such as herd (indirect) protection, changes to the prevalence of precancerous neoplasias, and other HPV-related endpoints including non-cervical cancers and anogenital warts. Such events are important to address more complex policy questions such as catch-up and male vaccination, the choice between bivalent and quadrivalent HPV vaccines, and the interaction between vaccination and screening when both are introduced around the same time. The advantage of PRIME is that it is straightforward enough to be used by non-experts and has fairly light data requirements. For example, estimates of population-based HPV prevalence or of cervical neoplasias (which are not available in most countries with a high burden of cervical cancer) are not required.
The potential eff ect of exclusion of herd immunity is diffi cult to estimate because published models do not disaggregate direct and indirect eff ects on outcomes. One review 9 of studies in high-income countries suggested that inclusion of indirect eff ects decreased cost-eff ectiveness ratios by 23-44%. A review in LMICs suggested much larger diff erences, with median costeff ectiveness ratios of I$10 263 for static models and I$650 for dynamic models. 8 However, between-model comparisons need to be treated with caution because
Figure 4: (A) Number of GAVI-72 countries that have introduced human papillomavirus (HPV) vaccination, (B) annual number of girls vaccinated, (C) annual number of cervical cancers prevented, and (D) annual number of deaths prevented by vaccination in those countries
Three scenarios are shown: (1) no further vaccine introductions or increases in coverage beyond 2014 (worst case), (2) introductions according to GAVI strategic demand forecasts, and (3) the entire cohort of 12-year olds in every GAVI-72 country is vaccinated every year from 2014 (best case). Shaded regions show the range of results in sensitivity analyses when cancer incidence and mortality are varied by ±25%. A and B have no shaded regions because varying the epidemiological parameters has no eff ect on the coverage of vaccination. models that realistically incorporate indirect eff ects (dynamic models) are largely produced by a small number of modelling groups who might have made other modelling choices (besides inclusion of indirect eff ects) that diff erentiate them from other models. Our analysis suggests that the potential of HPV vaccination has yet to be realised, because if no new GAVI-72 countries introduce HPV vaccination after 2013, only 2000 of more than 400 000 potential vaccinepreventable cancer cases in these countries would be prevented every year. Introduction of vaccines supported by the GAVI Alliance could prevent around half these cases, showing the importance of both GAVI support and access to low vaccine prices for HPV vaccination, but also the magnitude of the challenge remaining even after present projected levels of GAVI support.
Our analysis also emphasises between-country inequalities in vaccine introductions so far, in which most countries with the highest preventable burden of cervical cancer-related HPV vaccination are yet to introduce country-level programmes. The same countries without HPV vaccination programmes are also less likely to have country-specifi c information from published economic evaluations about the potential health eff ect, budget implications, and cost-eff ectiveness of vaccination that decision makers need. PRIME is straightforward enough to be used at a local level to support country-level data collection, model parameterisation, and evidence-based decision-making. This simplicity will enable countries to do their own analyses with local assumptions, data, and expertise, which could enhance the eff ect that results have on national decision making.
Panel: Research in context
Systematic review
We recently systematically reviewed all cost-eff ectiveness analyses of HPV vaccination in low-income and middle-income countries (LMICs) published in PubMed, Embase, and the Cochrane Library published up to April 1, 2012. 8 Our review identifi ed 25 cost-eff ectiveness evaluations. However, most LMICs only had vaccine projections of vaccine eff ect and cost-eff ectiveness from multicountry studies with little involvement of local analysts. Hence, we developed an HPV economic model that was simple enough to be used at a local level for country-led data collection and model parameterisation to support evidence-based decision-making, yet could reasonably reproduce the results of more complex models for the cost-eff ectiveness of vaccination of girls before sexual debut.
Interpretation
Our model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), provides similar results to those obtained by more complex cost-eff ectiveness models, for evaluation of HPV vaccination of girls before sexual debut. A global analysis with PRIME suggests that HPV vaccination is likely to be cost eff ective in almost every country, and especially low-income countries. However, the potential of vaccination has yet to be realised because countries with the highest vaccine-preventable burden of cervical cancer have largely not introduced country-level programmes. Empowering local decision makers to do their own cost-eff ectiveness analyses might facilitate vaccine introduction in countries that most need it.
